Article
Oncology
Liva K. K. Stuhr, Kasper Madsen, Astrid Z. Z. Johansen, Inna M. M. Chen, Carsten P. P. Hansen, Lars H. H. Jensen, Torben F. F. Hansen, Kirstine Klove-Mogensen, Kaspar R. R. Nielsen, Julia S. S. Johansen
Summary: The CA 19-9 blood test has been widely used as a biomarker for pancreatic ductal adenocarcinoma (PDAC), but new biomarkers are needed to improve diagnosis. In this study, we found that combining the CA 19-9 test with the sCD163 blood test provided better diagnostic results compared to CA 19-9 alone. These findings suggest that sCD163 could be a valuable diagnostic marker for PDAC.
Article
Biochemistry & Molecular Biology
Tadataka Takagi, Rina Fujiwara-Tani, Shiori Mori, Shingo Kishi, Yukiko Nishiguchi, Takamitsu Sasaki, Ruiko Ogata, Ayaka Ikemoto, Rika Sasaki, Hitoshi Ohmori, Yi Luo, Ujjal Kumar Bhawal, Masayuki Sho, Hiroki Kuniyasu
Summary: Gemcitabine resistance in pancreatic ductal adenocarcinoma cells is associated with decreased energy production, decreased mitochondrial reactive oxygen species levels, and increased stemness caused by mitochondrial damage. Hypoxia may promote this process. Treatment with lauric acid restores gemcitabine sensitivity by activating oxidative phosphorylation. Further clinical validation of lauric acid in gemcitabine resistance is needed in the future.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Analytical
Amy Makler, Ramaswamy Narayanan, Waseem Asghar
Summary: Exosomal miRNA may be used for early detection of PDAC and potentially differentiate patients with chronic pancreatitis, neoplasms, and PDAC. The study identified 18 miRNA with strong potential, and 7 mature miRs showed statistical significance in exosomal RNA.
Article
Immunology
Hongkai Zhuang, Shujie Wang, Bo Chen, Zedan Zhang, Zuyi Ma, Zhenchong Li, Chunsheng Liu, Zixuan Zhou, Yuanfeng Gong, Shanzhou Huang, Baohua Hou, Yajin Chen, Chuanzhao Zhang
Summary: The study established a specific HIF-1 score system to discriminate PDAC with various hypoxia statuses and immune microenvironments. For highly hypoxic and immunosuppressive tumors, a combination treatment strategy should be considered in the future.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Masato Ono, Yusuke Ono, Toru Nakamura, Takahiro Tsuchikawa, Tomotaka Kuraya, Shota Kuwabara, Yoshitsugu Nakanishi, Toshimichi Asano, Aya Matsui, Kimitaka Tanaka, Yuma Ebihara, Yo Kurashima, Takehiro Noji, Soichi Murakami, Toshiaki Shichinohe, Tomoko Mitsuhashi, Yuko Omori, Toru Furukawa, Kenzui Taniue, Mayumi Suzuki, Ayumu Sugitani, Hidenori Karasaki, Yusuke Mizukami, Satoshi Hirano
Summary: This study found that carbohydrate antigen 19-9 (CA19-9), SMAD4, and TP53 mutation scoring can effectively distinguish short-term recurrences from long-term survivors in pancreatic cancer patients. The mutation types of TP53 gene are closely related to the nuclear expression of p53, and the combination of SMAD4 abnormalities and TP53 mutation types can better differentiate different groups of patients.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Liwei Cao, Chen Huang, Daniel Cui Zhou, Yingwei Hu, T. Mamie Lih, Sara R. Savage, Karsten Krug, David J. Clark, Michael Schnaubelt, Lijun Chen, Felipe da Veiga Leprevost, Rodrigo Vargas Eguez, Weiming Yang, Jianbo Pan, Bo Wen, Yongchao Dou, Wen Jiang, Yuxing Liao, Zhiao Shi, Nadezhda Terekhanova, Song Cao, Rita Jui-Hsien Lu, Yize Li, Ruiyang Liu, Houxiang Zhu, Peter Ronning, Yige Wu, Matthew A. Wyczalkowski, Hariharan Easwaran, Ludmila Danilova, Arvind Singh Mer, Seungyeul Yoo, Joshua M. Wang, Wenke Liu, Benjamin Haibe-Kains, Mathangi Thiagarajan, Scott D. Jewell, Galen Hostetter, Chelsea J. Newton, Qing Kay Li, Michael H. Roehr, David Fenyo, Pei Wang, Alexey Nesvizhskii, D. R. Mani, Gilbert S. Omenn, Emily S. Boja, Mehdi Mesri, Ana Robles, Henry Rodriguez, Oliver F. Bathe, Daniel W. Chan, Ralph H. Hruban, Li Ding, Bing Zhang, Hui Zhang
Summary: This study conducted comprehensive proteogenomic analysis of PDAC to understand the molecular alterations that drive oncogenesis. Multiple analyses were performed on tissues from patients, providing valuable resources for early detection and identification of therapeutic targets.
Review
Biochemistry & Molecular Biology
Nausika Betriu, Juan Bertran-Mas, Anna Andreeva, Carlos E. Semino
Summary: Syndecans, a subfamily of proteoglycans, play critical roles in various physiological processes and have implications in disease progression. Their interactions with other macromolecules contribute to normal cellular functions and disease pathogenesis.
Article
Medicine, General & Internal
Yongfeng Xu, Qunli Xiong, Yang Yang, Ningna Weng, Junjun Li, Jinlu Liu, Xiaojuan Yang, Zhu Zeng, Zhiwei Zhang, Qing Zhu
Summary: The expression of NRDC is associated with clinical characteristics in pancreatic ductal adenocarcinoma, and it may serve as a circulating biomarker to evaluate the aggressive clinical features in patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Anna Maria Nurmi, Harri Mustonen, Caj Haglund, Hanna Seppanen
Summary: Changes in CRP and CA19-9 levels during preoperative oncological therapy are predictive factors for postoperative survival in PDAC patients. A higher CRP level after therapy indicates poorer prognosis, while a >90% decrease in CA19-9 level predicts a better outcome.
Article
Cell Biology
Liting Lu, Dandan Zheng, Junchi Qu, Yanyan Zhuang, Juanfei Peng, Sihua Lan, Shineng Zhang, Fengting Huang
Summary: This research investigates the role of m(6)A regulators in pancreatic ductal adenocarcinoma (PDA) and identifies METTL16 as a potential biomarker and immunotherapy target that could regulate the tumor microenvironment and promote antitumor immunity.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Yingying Cao, Rui Zhao, Kai Guo, Shuai Ren, Yaping Zhang, Zipeng Lu, Lei Tian, Tao Li, Xiao Chen, Zhongqiu Wang
Summary: This study developed a novel metabolic model using both serum and tissue samples for early detection of stage-I pancreatic ductal adenocarcinoma (PDAC). The model showed high diagnostic accuracy and outperformed the traditional CA19-9 marker.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Min Ren, Liaoliao Feng, Rongrong Zong, Huiru Sun
Summary: This study aims to establish a hypoxia-related risk scoring model that can effectively predict the prognosis and chemotherapy outcomes of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC).
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Immunology
Dongjie Chen, Hui Huang, Longjun Zang, Wenzhe Gao, Hongwei Zhu, Xiao Yu
Summary: By analyzing gene expression data of PDAC patients, we constructed a risk score model with seven signature genes that can effectively predict patient prognosis, stratifying patients into high-risk and low-risk groups. Patients in the low-risk group showed significantly better overall survival compared to those in the high-risk group.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Maria Urbanova, Verona Buocikova, Lenka Trnkova, Sabina Strapcova, Viera Horvathova Kajabova, Emma Barreto Melian, Maria Novisedlakova, Miroslav Tomas, Peter Dubovan, Julie Earl, Jozef Bizik, Eliska Svastova, Sona Ciernikova, Bozena Smolkova
Summary: Pancreatic ductal adenocarcinoma (PDAC) is characterized by severe hypoxia, and DNA methylation plays an important role in PDAC aggressiveness and epithelial-to-mesenchymal transition (EMT). Inhibiting DNA methylation can reactivate silenced genes and potentially be targeted for PDAC progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Eleonora Lai, Pina Ziranu, Dario Spanu, Marco Dubois, Andrea Pretta, Simona Tolu, Silvia Camera, Nicole Liscia, Stefano Mariani, Mara Persano, Marco Migliari, Clelia Donisi, Laura Demurtas, Valeria Pusceddu, Marco Puzzoni, Mario Scartozzi
Summary: Despite ongoing research, there is still insufficient data on BRCA1/2-mutant PDAC, and more understanding is needed on the specific landscape of PDAC with BRCA mutations.
BRITISH JOURNAL OF CANCER
(2021)